U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06939686) titled 'Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing' on April 15.
Brief Summary: This study is a prospective, randomized controlled trial designed to evaluate the effectiveness of Miro3D Wound Matrix plus Standard of Care (SOC) compared to SOC alone in treating Wagner Grade 1 diabetic foot ulcers (DFUs) and wound dehiscence in an outpatient setting. The trial is sponsored by Reprise Biomedical, Inc. and aims to explore whether the addition of Miro3D-a three-dimensional, acellular porcine-derived wound matrix-enhances wound healing outcomes compared to SOC alone.
Purpose of the Study: The primary purpose of the stu...